Publicado ennews/estado, Noticia Local

TRIGR Therapeutics Announces Publication of TR009/ABL001, Dual Angiogenic Bispecific Antibody Targeting VEGF/DLL4, in the International Journal of Molecular Sciences

IRVINE, Calif., Jan. 6, 2021 /PRNewswire/ — TRIGR Therapeutics, Inc. («TRIGR»), a clinical stage biopharmaceutical company focused on the development of multi-targeted angiogenic and immunomodulatory bispecific antibodies for oncology and certain ischemic indications, announced today the publication of a manuscript in the International Journal of Molecular Sciences, highlighting the pre-clinical development of TR009, the Company’s investigational […]